Literature DB >> 11236025

HER-2/neu (erbB-2) and the cell cycle.

D Busse1, R S Doughty, C L Arteaga.   

Abstract

Signaling by the HER-2 proto-oncogene product results in the activation of several biochemical pathways, which in turn modulate the expression and function of cell cycle regulators. These alterations of cell cycle regulatory molecules may be critical for the conception and maintenance of the transformed phenotype conferred by HER-2 gene amplification and overexpression. On the other hand, blockade of HER-2 function with a therapeutic intent will require the reversal of these effects on cell cycle regulatory molecules in order for these interventions to be effective. Data is presented to suggest that the G1 cyclin D1 and the cyclin-dependent kinase inhibitor p27KIP1 may be involved in subversion of the G1/S traverse by signaling pathways activated by HER-2 function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11236025

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  Neuregulin-mediated ErbB3 signaling is required for formation of zebrafish dorsal root ganglion neurons.

Authors:  Yasuko Honjo; Jonathan Kniss; Judith S Eisen
Journal:  Development       Date:  2008-07-03       Impact factor: 6.868

Review 2.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

3.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

Review 4.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

5.  Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas.

Authors:  Rina Kato; Kiyoshi Hasegawa; Risa Ishii; Akiko Owaki; Yutaka Torii; Shuko Oe; Hiroshi Hirasawa; Yoichi Kobayashi; Yasuhiro Udagawa
Journal:  Onco Targets Ther       Date:  2013-08-07       Impact factor: 4.147

6.  The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling.

Authors:  Duo Han; Shaihong Zhu; Xia Li; Zhiqiang Li; Hui Huang; Wenzhe Gao; Yunfei Liu; Hongwei Zhu; Xiao Yu
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

7.  Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model.

Authors:  Christof Renner; Nadine Zemitzsch; Beate Fuchs; Kathrin D Geiger; Matthias Hermes; Jan Hengstler; Rolf Gebhardt; Jürgen Meixensberger; Frank Gaunitz
Journal:  Mol Cancer       Date:  2010-01-06       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.